Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency cl...

por Allahyari, Abolghasem, Ehsanpour, Ali, Ansarinejad, Nafiseh, Mehrzad, Valiollah, Kalantari, Behjat, Raafat, Jahangir, Ghadiany, Mojtaba, Shahi, Farhad, Gharib, Behrooz, Moazed, Vahid, Khosravi, Adnan, Mirpour, Mir Hossein, Salari, Sina, Mortazavizadeh, Seyedmohammadreza, Nekoyi, Amirabbas, Khani, Mohsen, Sadeghi, Alireza, Gharib, Sirus, Bary, Alireza, Mirzania, Mehrzad, Haghighat, Shirin, Razavi, Seyed Mohsen, Emami, Seyed Amir Hossein, Hosseinzadeh, Mehran, Mirbolouk, Mahdi, Sadighi, Sanambar, Shahrasbi, Abdolali, Esfahani, Ali, Gity, Masoumeh, Anjidani, Nassim, Kafi, Hamidreza, Najafi, Safa
Publicado 2022

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, eq...

por Allahyari, Abolghasem, Ehsanpour, Ali, Najafi, Behrouz, Ansarinejad, Nafseh, Mehrzad, Valiollah, Kalantari, Behjat, Raafat, Jahangir, Ghadiany, Mojtaba, Shahi, Farhad, Gharib, Behrooz, Moazed, Vahid, Khosravi, Adnan, Mirpour, Mir Hossein, Salari, Sina, Mortazavizadeh, Seyedmohammadreza, Nekoyi, Amirabbas, Khani, Mohsen, Sadeghi, Alireza, Gharib, Sirus, Bary, Alireza, Mirzania, Mehrzad, Haghighat, Shirin, Razavi, Seyed Mohsen, Emami, Seyed Amir Hossein, Hosseinzadeh, Mehran, Mirbolouk, Mahdi, Sadighi, Sanambar, Shahrasbi, Abdolali, Esfahani, Ali, Gity, Masoumeh, Anjidani, Nassim, Kaf, Hamidreza, Najaf, Safa
Publicado 2022